Voltaren Archives - Inside FMCG

GSK, Novartis ordered to pay $4.5m for misleading Voltaren claims

Novartis and GSK penalised for making false and misleading claims in the marketing of Voltaren Osteo Gel.

GSK and Novartis face penalties for misleading consumers on Voltaren products

GSK and Novartis admit that they breached Australian Consumer Law in marketing of Voltaren.